I bleed Biogen: Just months after the big biotech was slammed following the controversial OK of aducanumab, R&D chief Al Sandrock makes an abrupt exit – Endpoints News

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.